ALKEM2019-07-012019-09-30in-bse-fin:OneOperatingExpenses01Member ALKEM2019-07-012019-09-30in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ALKEM 2019-04-01 2020-03-31 2019-10-18 INR Millions Half yearly Single segment The Company is exclusively engaged in pharmaceutical business 2019-07-01 2019-09-30 Unaudited Consolidated 22640300000.00 314200000.00 22954500000.00 5284700000.00 3668200000.00 90100000.00 3896300000.00 177500000.00 564000000.00 5175100000.00 18855900000.00 4098600000.00 0.00 4098600000.00 776500000.00 -483100000.00 293400000.00 0.00 3805200000.00 0.00 0.00 0.00 0.00 3805200000.00 86900000.00 3892100000.00 3708500000.00 96700000.00 3800400000.00 91700000.00 239100000.00 2 31.02 31.02 0.00 0.00 31.02 31.02 1) The above unaudited consolidated financial results of the Company were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 11 November 2019. The figures for the quarter and six months ended 30 September 2019 have been subjected to limited review by the statutory auditors. The auditors have expressed an unmodified opinion on the financial results for the quarter and six months ended 30 September 2019. n n2) Effective 1 April 2019, the Group has adopted Ind AS 116 Leases applicable to all contracts having lease components existing on 1 April 2019 using modified retrospective approach. This has resulted in recognising right of use asset and a corresponding lease liability of Rs.947.2 million as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from lease rent to depreciation cost for the right of use asset and finance cost for interest accrued on lease liability. Due to this change, profit before tax for the quarter and six months ended 30 September 2019 is lower by Rs.6.3 million and Rs.11.9 million respectively. Consequent to adoption of Ind AS 116, there is no impact on retained earnings as on 1 April 2019 resulting in no restatement in results of comparative period. n n3) Pursuant to the Taxation Law (Amendment) Ordinance, 2019 ('Ordinance') issued by Ministry of Law and Justice (Legislative Department) on 20 September 2019 which is effective 1 April 2019, domestic companies have the option to pay corporate income tax rate at 22% plus applicable surcharge and cess subject to certain conditions. The Company and its subsidiaries incorporated in India have made an assessment of the impact of the Ordinance and decided to continue with the existing tax structure until utilisation of accumulated minimum alternative tax (MAT) credit. n n4) The Board of Directors at its meeting held on 30 May 2019 had recommended a final dividend of Rs. 8 (Rupees eight only) per equity share (400.0 % on the face value of Rs. 2 each) for the financial year 2018-19 which was paid during the quarter ended 30 September 2019. n n5) The Group operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment has been made. 2019-04-01 2019-09-30 Unaudited Consolidated 41135300000.00 488900000.00 41624200000.00 10738400000.00 7112100000.00 -1689300000.00 7799500000.00 338700000.00 1122300000.00 10003700000.00 35425400000.00 6198800000.00 0.00 6198800000.00 1411300000.00 -890600000.00 520700000.00 0.00 5678100000.00 0.00 0.00 0.00 0.00 5678100000.00 -53800000.00 5624300000.00 5563200000.00 114900000.00 5516900000.00 107400000.00 239100000.00 2 46.53 46.53 0.00 0.00 46.53 46.53 Other expenses 5175100000.00 Other expenses 10003700000.00